Pfizer CTI Research Network Expands With NIH Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.
You may also be interested in...
AstraZeneca Has Stake In Three Of Nine NCATS Research Projects
Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.
Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
NIH Translational Science Center Becomes A (Cash-limited) Reality
NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.